News
This page is intended for media, analysts, and investors.
Read the latest Mereo BioPharma news
Together with patient communities, healthcare professionals, commercial partners and with the support of investors, we are constantly making progress on our mission. We are committed to regularly updating our investors, analysts, and the media on this progress. Here you can read the latest Mereo news and learn about events at which we are speaking.
If you would like to get in touch, you will find ways to contact us on this page.
Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
London, UK, Solana Beach, California, and Ahmedabad, India – August 11, 2026 – Mereo BioPharma Group plc (Nasdaq: MREO), a clinical-stage biopharmaceutical company focused on rare diseases and Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited, today announced that they have entered into an option and license agreement for the U.S. commercial and global manufacturing rights to alvelestat for AATD-LD.
Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
London, August 11, 2026 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the second quarter ended June 30, 2026, and provided an update on recent corporate highlights.
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference 2026
London, June 2, 2026 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference 2026 on Thursday, June 4, 2026, at 9:55 EDT/ 14:55 BST.
Mereo BioPharma Reports Full Year 2021 Financial Results and Recent Highlights
Mereo BioPharma today announced financial results for the year ended December 31, 2021 and provided an update on recent corporate highlights.
Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights
London , March 28, 2023 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the year ended December 31, 2022 and provided an update on recent corporate highlights.
Mereo BioPharma Announces Appointment of Anne Hyland to Board of Directors
Mereo BioPharma today announced the appointment of Anne Hyland to the Company’s Board of Directors.
UAB and Mereo Announce Positive Top-line Results from “COSTA” a Phase 1b/2 Trial of Alvelestat (MPH966) in Hospitalized Patients with COVID-19 Respiratory Disease
Alvelestat was reported safe and well-tolerated in patients with COVID-19. Alvelestat on top of standard of care resulted in a more rapid time to improvement in WHO Disease Severity score of >=2 in the first 5-7 days compared to placebo plus standard of care
Biomarker Data from Phase 1b/2 Investigator-sponsored Trial of Mereo’s Alvelestat in Bronchiolitis Obliterans Syndrome (BOS) at the ASH Annual Meeting
Mereo BioPharma announced the presentation of data from the initial seven patients in an investigator-sponsored study of alvelestat in patients with BOS following hematopoietic stem cell transplantation (“HCT”)
Mereo BioPharma Reports Interim Data from ACTIVATE Phase 1b/2 Open Label Study of etigilimab Anti-TIGIT Antibody in combination with Nivolumab in Solid Tumors
Mereo BioPharma today reported promising interim efficacy, safety, and biomarker data on patients from ACTIVATE, a Phase 1b/2 study of its anti-TIGIT antibody, etigilimab, in combination with nivolumab in select recurrent advanced / metastatic solid tumors
Data from Investigator-sponsored Trial of Mereo BioPharma’s alvelestat in Bronchiolitis Obliterans Syndrome (BOS) Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting
Mereo BioPharma announced that data from an investigator-sponsored study of alvelestat in patients with Bronchiolitis Obliterans Syndrome (“BOS”) following hematopoietic stem cell transplantation (“HCT”) will be shared in a poster presentation at the 2021 American Society of Hematology (ASH) Annual Meeting, being held December 11-14, 2021 in Atlanta, Georgia
Mereo BioPharma Receives U.S. Orphan Drug Designation for alvelestat in the Treatment of alpha-1 antitrypsin deficiency
Mereo BioPharma today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to alvelestat for the treatment of alpha-1 antitrypsin deficiency (AATD).
Mereo BioPharma, the Osteogenesis Imperfecta Federation Europe (OIFE) and the Osteogenesis Imperfecta Foundation (OIF) announces completion of the IMPACT Survey enrollment
Living With Osteogenesis IMPerfecta: UnderstAnding Experiences Based On Community InsighT and Evidence Survey, the IMPACT Survey More than 2200 individual responses collected over a 3-month period from some 65 countries in 8 languages Set to be the largest global gathering of data to date
Raising awareness around Alpha-1 Antitrypsin Deficiency
Recently, we worked with the AATD community on a campaign to increase disease awareness and encourage testing.
Mereo BioPharma and Ultragenyx Present Data from the Phase 2b ASTEROID Study of UX143 (setrusumab) in Osteogenesis Imperfecta (OI) at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting
Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group presented secondary endpoint data on UX143 (setrusumab) from the Phase 2b ASTEROID study for the Treatment of Osteogenesis Imperfecta (OI). Data were presented at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting
Mereo BioPharma Announces Appointment of Pierre Jacquet, M.D., Ph.D. to Board of Directors
Mereo BioPharma today announced the appointment of Pierre Jacquet , M.D., Ph.D to the Company’s Board of Directors, effective September 20, 2021.
